Clinical Trial Update: An Efficacy and Safety Study of Anti-TNF Monoclonal Antibody in Patients With Fistulizing Crohn's Disease [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the efficacy and safety of an anti-TNF monoclonal antibody in fistulizing Crohn's disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease

Drugs mentioned

• Infliximab (infliximab)

Snippet

Sponsor: Centocor, Inc. | Conditions: Crohn Disease | Phase 3 | Status: COMPLETED